SynPhNe

SynPhNe operates across medical devices, rehabilitation, digital health, and wearable technology. Its stated product distinction is combining brain and muscle training in one connected wearable system, rather than presenting the device solely as a general-purpose fitness tracker or a standalone exercise aid. The company describes use cases spanning neurological rehabilitation, including recovery after stroke or traumatic brain injury, as well as cognitive and physical functional support. Its Hospital to Home Program extends the offering beyond a device toward care continuity between clinical rehabilitation and recovery at home. SynPhNe’s $10.96 million in reported funding, including a $5 million Series A in 2024, indicates external financing to develop its offering; funding alone does not establish market share or clinical validation. Evidence on customer numbers, reimbursement, regulatory clearances, and comparative outcomes is limited, leaving its competitive standing difficult to quantify.

SynPhNe was founded in 2013 and has raised $10.96 million across three disclosed rounds: a $960,000 seed round dated Jul 1, 2016, a $5 million convertible note dated Dec 31, 2022, and a $5 million Series A dated Mar 11, 2024. The Series A, led by Event Horizon Technologies, is the clearest financing inflection point in the available history. The company announced a next-generation wearable on Mar 5, 2025, describing a focus on cognitive and physical function restoration. Its product lineup also includes ENABler Technology and a Hospital to Home Program, indicating an approach that pairs wearable training with a care pathway. The available employee band is 11–50, but no reliable time series is provided to establish hiring or headcount growth; only one current leadership position is listed. Overall, the record points to continued product development and a shift toward broader deployment following the 2024 financing, while the scale and pace of customer, clinical, and geographic expansion remain unclear.